Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lesinidase alfa

Next Previous
Search
Drug Profile

Lesinidase alfa

Alternative Names: Recombinant alpha-N-acetyl-glucosaminidase (rhNAGLU) - Alexion; SBC-103

Latest Information Update: 29 Jul 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synageva BioPharma
  • Developer Alexion AstraZeneca Rare Disease
  • Class Acetylglucosaminidases; Enzymes; Glycoside hydrolases; Recombinant proteins
  • Mechanism of Action Alpha N acetyl D glucosaminidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis III

Most Recent Events

  • 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
  • 17 Apr 2018 Alexion Pharmaceuticals terminates a phase I/II trial in Mucopolysaccharidosis III (In children, Treatment-naive) in United Kingdom after review of the data from all interventional clinical studies of SBC-103 (NCT02618512)
  • 16 Feb 2017 Alexion Pharmaceuticals does not intend to expand a phase I/II trial in Mucopolysaccharidosis III (In children) (NCT02324049)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top